Agena Bioscience is a provider of targeted genomic analysis solutions, centered on its proprietary MassARRAY System which combines PCR with MALDI-TOF mass spectrometry. The company serves the research and clinical diagnostics markets with a focus on pharmacogenetics, oncology mutation profiling, hereditary genetics, and sample integrity testing. As a division of Mesa Labs, Agena operates globally with a business model based on selling instruments, consumable assays, and related services to molecular laboratories.
OncologyGenetic DisordersPharmacogenomics
Technology Platform
MassARRAY System combining PCR with MALDI-TOF mass spectrometry for highly multiplexed, targeted genetic variant detection.
Funding History
7
Total raised:$310M
Series D$100MUndisclosed
Series C$50MUndisclosed
Series C$50MUndisclosed
Series B$40MUndisclosed
Opportunities
The growing clinical adoption of pharmacogenetics, driven by professional society guidelines, creates a significant market for standardized, targeted panels.
Expansion in liquid biopsy testing for oncology and international market growth, particularly with regulatory clearances in Europe and China, present further avenues for expansion.
Risk Factors
Intense competition from next-generation sequencing and other targeted analysis technologies that may offer lower cost or broader analysis.
Regulatory hurdles and slow clinical adoption rates for new genetic tests can impact the commercialization of new panels.
Competitive Landscape
Agena competes in the targeted genomic analysis space against companies offering qPCR/digital PCR solutions (e.g., Bio-Rad, Qiagen) and targeted NGS panels (e.g., Illumina, Thermo Fisher). Its differentiation lies in the multiplexing flexibility and cost-effectiveness of the MassARRAY platform for medium-to-high plex applications.
